cetirizine has been researched along with Abnormalities, Drug-Induced in 3 studies
Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.
cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.
Abnormalities, Drug-Induced: Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the safety of cetirizine during pregnancy." | 7.74 | The safety of cetirizine during pregnancy. A prospective observational cohort study. ( Schaefer, C; Weber-Schoendorfer, C, 2008) |
| "To assess the safety of cetirizine during pregnancy." | 3.74 | The safety of cetirizine during pregnancy. A prospective observational cohort study. ( Schaefer, C; Weber-Schoendorfer, C, 2008) |
| " The objective was to measure the rate of adverse pregnancy outcomes." | 2.50 | The fetal safety of cetirizine: an observational cohort study and meta-analysis. ( Boskovic, R; Djokanovic, N; Etwel, F; Koren, G; Martinovic, J; Moretti, ME, 2014) |
| " However, this activity may be missed in conventional teratology studies because repeat dosing may cause resorptions." | 1.36 | Improved methodology for identifying the teratogenic potential in early drug development of hERG channel blocking drugs. ( Bengtsson, E; Blomgren, B; Danielsson, BR; Danielsson, C; Johansson, A; Khan, KM; Kultima, K; Nilsson, MF; Sköld, AC; Webster, WS; Wilson, J, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Etwel, F | 1 |
| Djokanovic, N | 1 |
| Moretti, ME | 1 |
| Boskovic, R | 1 |
| Martinovic, J | 1 |
| Koren, G | 1 |
| Weber-Schoendorfer, C | 1 |
| Schaefer, C | 1 |
| Nilsson, MF | 1 |
| Danielsson, C | 1 |
| Sköld, AC | 1 |
| Johansson, A | 1 |
| Blomgren, B | 1 |
| Wilson, J | 1 |
| Khan, KM | 1 |
| Bengtsson, E | 1 |
| Kultima, K | 1 |
| Webster, WS | 1 |
| Danielsson, BR | 1 |
1 review available for cetirizine and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
The fetal safety of cetirizine: an observational cohort study and meta-analysis.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Cetirizine; Female; Histamine H1 Antagoni | 2014 |
2 other studies available for cetirizine and Abnormalities, Drug-Induced
| Article | Year |
|---|---|
The safety of cetirizine during pregnancy. A prospective observational cohort study.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adolescent; Adult; Birth Weight; Cetirizine; Fem | 2008 |
Improved methodology for identifying the teratogenic potential in early drug development of hERG channel blocking drugs.
Topics: Abnormalities, Drug-Induced; Animals; Astemizole; Cetirizine; Drug Evaluation, Preclinical; Embryo C | 2010 |